×
ElectroCore Total Long Term Liabilities 2017-2024 | ECOR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ElectroCore total long term liabilities from 2017 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
ElectroCore Total Long Term Liabilities 2017-2024 | ECOR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ElectroCore total long term liabilities from 2017 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.5B
Takeda Pharmaceutical (TAK)
$43.4B
Merck (MKKGY)
$21B
Astellas Pharma (ALPMY)
$20.3B
Sandoz Group AG (SDZNY)
$19.9B
United Therapeutics (UTHR)
$17.9B
Summit Therapeutics (SMMT)
$16.1B
Neurocrine Biosciences (NBIX)
$12.9B
Shionogi (SGIOY)
$12.3B
Catalent (CTLT)
$10.8B
Jazz Pharmaceuticals (JAZZ)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Orion OYJ (ORINY)
$6.8B
Corcept Therapeutics (CORT)
$6.2B
Ionis Pharmaceuticals (IONS)
$6.1B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.8B
Dyne Therapeutics (DYN)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.8B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
Soleno Therapeutics (SLNO)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2.2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Harrow (HROW)
$1.8B
Evotec AG (EVO)
$1.7B
Ocular Therapeutix (OCUL)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.7B
ARS Pharmaceuticals (SPRY)
$1.7B